Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

Table 1 The impact of CYP2D*6 genotype in clinical parameters

Ref.	Parameter	Extensive metabolisers	Intermediate metabolisers	Poor metamolisers
Goetz et al[8]	RFS DFS OS		NS (P = 0.075) NS (P = 0.097) NS	Worse (P = 0.005) Worse (P = 0.008) NS
Scroth et al[9,10]	RR MR	14.90% 16.70%	20.90% 18.00%	29.00% 22.80%
Ramóny Cajal et al[12]	DFS	118 mo	114 mo	98 mo
Bijl et al[13]	RBCM		NS	Increased (P = 0.041)
Newman et al[16]	OS			Worse
Karle et al[17]	PFS	14 mo		9 mo
Abraham et al[20]	BCSS			NS
Nowell[23]	BCR, OS		NS	NS
Rae et al[25]	RR		NS	NS
Regan et al[26]	BCE		NS	NS

RFS: Relapse free survival; DFS: Disease free survival; OS: Overall survival; RR: Recurrence rate; MR: Mortality rate; RBCM: Risk of breast cancer mortality; PFS: Progression free survival; BCSS: Breast cancer specific survival; BCR: Breast cancer relapse; BCE: Breast cancer events; NS: Non-significant difference.